Second-generation antipsychotics and metabolic side-effects: Canadian population-based study.

Area of Science:

• Pharmacology
• Public Health
• Metabolic Health

Background:

• Second-generation antipsychotic (SGA) use has risen, but population-level data on metabolic effects remain limited.
• Understanding the association between SGA use and metabolic health is crucial for public health surveillance.

Purpose of the Study:

• To investigate the relationship between SGA use and various metabolic indicators in the general Canadian population.
• To assess changes in SGA prevalence and associated metabolic risks over time.

Main Methods:

• Utilized data from the Canadian Health Measures Survey (CHMS), a cross-sectional study of Canadians aged 3-79.
• Examined metabolic indicators including weight, BMI, waist circumference, hypertension, diabetes, and metabolic syndrome definitions.

Main Results:

• The prevalence of SGA use in Canadians tripled during the study period.
• SGA use was significantly associated with increased odds of hypertension (OR 1.94) and abdominal obesity (OR 2.62) in adults.

Conclusions:

• The Canadian population shows evidence of metabolic dysfunction linked to SGA use.
• A rapid increase in SGA prevalence since 2007 warrants attention regarding metabolic health monitoring.